Alain Badorc

This inventor holds 16 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Sanofi, Sanofi-Aventis, Elf Sanofi. Active years: 1988-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alain Badorc. Retrieved from https://idiyas.com/inventor/alain-badorc

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 16 (Patent Applications = 1)

% Patents Active = 93.8

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 123(Granted Patents)

Location History:

Portet, FR (1993)
Roquettes, FR (1988 - 2014)
Paris, FR (2014)

Company Filing History:

Years Active: 1988-2014

Loading Chart...

Areas of Expertise:

Imidazo[1,5-a]pyridine

Indolizine Derivatives

FGF Inhibitors

Pharmaceutical Compositions

Benzodiazepine

Thiazole Derivatives

Ischemic Events

Thienocyclopentanone

2-Hydroxythiophene

Enantiomer

Thiadiazoles

Oximes

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8633216 - Imidazo[1,5-a]pyridine derivatives, method for preparing same and pharmaceutical compositions containing same (2014-01-21),

2. 8623862 - [object Object] (2014-01-07),

3. 8034828 - Use of FGF inhibiting substituted 1,2,3 indolizine derivatives in the preparation of medicaments which can be used to treat diseases linked to pathological choroidal angiogenesis (2011-10-11),

4. 8008321 - Imidazo[1,5-a] pyridine derivatives, method for preparing same and pharmaceutical compositions containing same (2011-08-30),

5. 7803811 - 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, method for preparing them and pharmaceutical compositions containing them (2010-09-28),

6. 7553845 - Substituted indolizine 1,2,3,6,7,8 derivatives, FGFs inhibitors, a method for the preparation thereof and pharmaceutical compositions containing said derivatives (2009-06-30),

7. 7442708 - 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same (2008-10-28),

8. 5798353 - Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one (1998-08-25),

9. 5719143 - Polysubstituted 3-acylamino-5-phenyl-1, 4-benzodiazepin-2-one (1998-02-17),

10. 5607952 - Substituted 4-phenylthiazole derivatives, process for their preparation (1997-03-04),

11. 5576328 - Method for the secondary prevention of ischemic events (1996-11-19),

12. 5534530 - 5-acylamino-1,2,4-thiadiazoles, their preparation and pharmaceutical (1996-07-09),

13. 5252749 - Ethers of thienocyclopentanone oximes, their preparation and (1993-10-12),

14. 5190938 - Derivatives of 2-hydroxythiophene and -furan fused with a (1993-03-02),

15. 4847265 - Dextro-rotatory enantiomer of methyl alpha-5 (4,5,6,7-tetrahydro (3,2-c) (1989-07-11),

Title: Alain Badorc: Innovator in Pharmaceutical Compositions

Introduction

Alain Badorc, an accomplished inventor located in Roquettes, France, has made significant contributions to the field of pharmaceuticals, holding a total of 16 patents. His innovative work focuses on developing new compounds and methods that have the potential to impact various therapeutic areas.

Latest Patents

One of Alain Badorc's latest patents involves Imidazo[1,5-a]pyridine derivatives, a method for preparing these compounds, and pharmaceutical compositions containing them. The invention concerns specific compounds of formula I, along with their therapeutic uses, showcasing Badorc's commitment to advancing pharmaceutical science.

Career Highlights

Throughout his career, Alain Badorc has worked with notable organizations, including Sanofi and Sanofi-Aventis, where he honed his expertise in drug development. His extensive work in these companies has underscored his role as a crucial player in the pharmaceutical innovation landscape.

Collaborations

Alain has collaborated with esteemed colleagues, including Daniel Frehel and Marie-Francoise Bordes. These partnerships reflect the collaborative spirit of innovation that drives advancements in the pharmaceutical field.

Conclusion

Alain Badorc’s contributions to pharmaceutical innovation are significant, with a focus on novel compounds and methods that push the boundaries of what is possible in therapeutic solutions. His extensive patent portfolio stands as a testament to his dedication and expertise in the industry.

Profile summary based on public USPTO records.